Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Baxter
AstraZeneca
Express Scripts
Healthtrust
Fuji
Medtronic
Boehringer Ingelheim
McKesson

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEFLAZACORT

« Back to Dashboard

Clinical Trials for Deflazacort

Trial ID Title Status Sponsor Phase Summary
NCT00243789 Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy Completed Cooperative International Neuromuscular Research Group Phase 1/Phase 2 The purpose of this study is to see if male children with Duchenne muscular dystrophy (DMD) have changes in strength when given the drug Pentoxifylline as a rescue treatment. A total of 64 subjects are expected to participate through all other centers of the Cooperative International Neuromuscular Research Group (CINRG) worldwide. The primary purpose of this study is to see whether the addition of pentoxifylline to a steroid regimen is effective in treating deteriorating muscle strength by comparing the muscle strength of PTX treated subjects and placebo treated subjects.
NCT00527228 Deflazacort in Dysferlinopathies Completed Ludwig-Maximilians - University of Munich Phase 2/Phase 3 The present study is designed to assess the natural history in a one year pre-phase of the trial and evaluate therapeutic efficacy and side effects of deflazacort in LGMD2B/MM patients in a placebo-controlled trial. Furthermore, long-term development of the disease under naturalistic conditions will be documented in a 2-year follow-up after the end of the double-blind treatment phase.
NCT01335295 Safety Study of Flavocoxid in Duchenne Muscular Dystrophy Completed University of Messina Phase 1 Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.
NCT01603407 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Recruiting National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.
NCT01603407 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Recruiting Newcastle University Phase 3 The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.
NCT01603407 Finding the Optimum Regimen for Duchenne Muscular Dystrophy Recruiting University Medical Center Freiburg Phase 3 The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Deflazacort

Condition Name

Condition Name for Deflazacort
Intervention Trials
Duchenne Muscular Dystrophy 6
Healthy Volunteers 2
Chronic Renal Disease 1
LGMD2B 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Deflazacort
Intervention Trials
Muscular Dystrophy, Duchenne 8
Muscular Dystrophies 8
Muscular Diseases 1
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Deflazacort

Trials by Country

Trials by Country for Deflazacort
Location Trials
United States 72
United Kingdom 6
Italy 5
Canada 4
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Deflazacort
Location Trials
California 5
Florida 5
Tennessee 4
Pennsylvania 4
District of Columbia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Deflazacort

Clinical Trial Phase

Clinical Trial Phase for Deflazacort
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Deflazacort
Clinical Trial Phase Trials
Completed 9
Recruiting 2
Not yet recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Deflazacort

Sponsor Name

Sponsor Name for Deflazacort
Sponsor Trials
Marathon Pharmaceuticals, LLC 7
Ludwig-Maximilians - University of Munich 1
Samsung Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Deflazacort
Sponsor Trials
Other 11
Industry 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
Cantor Fitzgerald
Chinese Patent Office
Fuji
Cipla
Fish and Richardson
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.